LENSAR INC (LNSR) Stock Price, Forecast & Analysis
NASDAQ:LNSR • US52634L1089
LNSR Key Statistics, Chart & Performance
The current stock price of LNSR is 11.97 USD. In the past month the price decreased by -2.68%. In the past year, price decreased by -7.92%.
LNSR Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to LNSR. When comparing the yearly performance of all stocks, LNSR turns out to be only a medium performer in the overall market: it outperformed 52.99% of all stocks.
LNSR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to LNSR. LNSR has a bad profitability rating. Also its financial health evaluation is rather negative.
LNSR Financial Highlights
Over the last trailing twelve months LNSR reported a non-GAAP Earnings per Share(EPS) of -4.39. The EPS decreased by -200.68% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -73.39% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
LNSR Forecast & Estimates
7 analysts have analysed LNSR and the average price target is 15.3 USD. This implies a price increase of 27.82% is expected in the next year compared to the current price of 11.97.
For the next year, analysts expect an EPS growth of -5.37% and a revenue growth 21.28% for LNSR
LNSR Ownership
LNSR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 20.26 | 202.318B | ||
| ISRG | INTUITIVE SURGICAL INC | 49.26 | 178.812B | ||
| SYK | STRYKER CORP | 25.62 | 148.172B | ||
| BSX | BOSTON SCIENTIFIC CORP | 21.94 | 113.97B | ||
| IDXX | IDEXX LABORATORIES INC | 44.32 | 52.44B | ||
| BDX | BECTON DICKINSON AND CO | 11.2 | 50.281B | ||
| EW | EDWARDS LIFESCIENCES CORP | 29.08 | 49.848B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.78 | 38.246B | ||
| RMD | RESMED INC | 20.87 | 37.332B | ||
| DXCM | DEXCOM INC | 29.08 | 28.639B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About LNSR
Company Profile
LENSAR, Inc. engages in the development of femtosecond laser technology for refractive cataract surgery. The company is headquartered in Orlando, Florida and currently employs 140 full-time employees. The company went IPO on 2020-09-21. The firm is focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. Its product portfolio includes the LENSAR Laser System (LLS), and the ALLY Robotic Cataract Laser Treatment System (ALLY). The firm has developed its ALLY Robotic Cataract Laser System as a compact, ergonomic system utilizing a fast dual-modality laser and integrating artificial intelligence (AI) into proprietary imaging and software. ALLY is designed to transform cataract surgery by utilizing the Company’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes its proprietary Streamline software technology, designed to guide surgeons to achieve better outcomes.
Company Info
LENSAR INC
2800 Discovery Drive, Suite 100
Orlando FLORIDA 32826 US
CEO: Nicholas Curtis
Employees: 140
Phone: 18885367271
LENSAR INC / LNSR FAQ
What does LENSAR INC do?
LENSAR, Inc. engages in the development of femtosecond laser technology for refractive cataract surgery. The company is headquartered in Orlando, Florida and currently employs 140 full-time employees. The company went IPO on 2020-09-21. The firm is focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. Its product portfolio includes the LENSAR Laser System (LLS), and the ALLY Robotic Cataract Laser Treatment System (ALLY). The firm has developed its ALLY Robotic Cataract Laser System as a compact, ergonomic system utilizing a fast dual-modality laser and integrating artificial intelligence (AI) into proprietary imaging and software. ALLY is designed to transform cataract surgery by utilizing the Company’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes its proprietary Streamline software technology, designed to guide surgeons to achieve better outcomes.
Can you provide the latest stock price for LENSAR INC?
The current stock price of LNSR is 11.97 USD. The price increased by 0.93% in the last trading session.
Does LENSAR INC pay dividends?
LNSR does not pay a dividend.
What is the ChartMill rating of LENSAR INC stock?
LNSR has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for LNSR stock?
7 analysts have analysed LNSR and the average price target is 15.3 USD. This implies a price increase of 27.82% is expected in the next year compared to the current price of 11.97.
Can you provide the PE ratio for LNSR stock?
LENSAR INC (LNSR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.39).